HU'S-MAP

Human and Species Monoclonal Antibody production

HU'S-MAP est accrédité par Lyonbiopôle

Identity card

Global budget: 1590 k€

Public funding: 1157 k€

Public funders: Grand Lyon, Oséo / BPI France (except FUI)

Call for projects: Autre

Year start: 2007

Completed project (2011-04)


Accredited by the French competitiveness cluster Lyonbiopôle


Strategic business area: Human Medicines

Application fields: Inflammatory diseases

Technological approaches / Keywords: Biologics, Immunotherapy

Stage of development at the beginning of the project: Discovery

Abstract

PX’Therapeutics has developed “customized” immunization technologies and cell fusion in semi-solid media. Finally, the company has developped humanization strategies for recombinant therapeutic mAb. In a joint effort, Px’Therapeutics and genOway have worked on the generation of two genetically modified mouse models to improve the selection of high-affinity antibodies and enhance their therapeutic quality. The third partner, INSERM Unit 851 has developed and selected fully human antiviral mAb directed against dengue serotypes aiming to produce “in vivo pre-validated” functional mAb.


Objectives

The HU’S-MAP project was aiming at developing broad antibody humanizationtechnologies and approaches through strong collaboration between biotechcompanies (Px’Therapeutics and GenOway) and academic laboratories (INSERMUnit 851). For this purpose, main activities were focused on production of partiallyhuman or full-human antibody by molecular biology, by generation of originalmouse models and by immortalization of human B lymphocytes.


Innovative assets
Highlights
Actual results
Perspectives

Innovative assets

PX’Therapeutics developed a subtractive immunization approach for weakly antigenic and/or rare epitopes. The cell fusion technology in semi-solid media stabilized low-secretor hybridomas. Finally, the humanization mAb procedure has speed up the manufacturing of therapeutic mAb. GenOway worked on the generation of two genetically modified mouse models based on replacement and insertion of a human gene or part of a gene of interest. INSERM Unit 851 has used the Epstein Barr Virus Immortalization technology to develop fully human anti-dengue mAb.

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte